David Hung, the founder and former chief executive of Medivation, an oncology-focused biopharma bought by US pharma giant Pfizer (NYSE: PFE) for $14 billion last year, has switched his attention to dementia in his role.
Dr Hung has been named CEO and chairman of Axovant Sciences (NYSE: AXON), a clinical-stage neurology company focused on the treatment of dementia and related neurological disorders.
"While I am proud of my accomplishments at Medivation, I aspire to even greater lasting accomplishments at Axovant"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze